1. Tuberculosis in the United States
National Tuberculosis Surveillance System
Highlights from 2007
Division of Tuberculosis Elimination
Centers for Disease Control and Prevention

2. Reported TB Cases* United States, 1982–2007
No. of Cases
Year
*Updated as of April 23, 2008.

3. TB Morbidity United States, 2002–2007
Year No Rate* , , , ,
13,
13,
*Cases per 100,000, updated as of April 23, 2008.

4. TB Case Rates,* United States, 2007
D.C.
< 3.5 (year 2000 target)
3.6–4.4
> 4.4 (national average)
*Cases per 100,000.

5. TB Case Rates* by Age Group United States, 1993–2007
Cases per 100,000
Age Group (years)
*Updated as of April 23, 2008.

6. Reported TB Cases by Age Group, United States, 2007
<15 yrs
(6%)
>65 yrs
(19%)
15–24 yrs
(12%)
25–44 yrs (32%)
45–64 yrs
(30%)

7. TB Case Rates by Age Group and Sex, United States, 2007
Cases per 100,000

8. TB Case Rates by Race/Ethnicity* United States, 1993–2007**
Cases per 100,000
White
Black or African-American
Hispanic
American Indian/Alaska Native
Asian/Pacific Islander
*All races are non-Hispanic. In 2003, Asian/Pacific Islander category includes persons who reported race as Asian only and/or Native Hawaiian or Other Pacific Islander only. **Updated as of April 23, 2008.

9. TB Case Rates by Age Group and Race/Ethnicity,* United States, 2007
Cases per 100,000
Age Group (yrs)
American Indian/Alaska Native
Asian
Black or African-American
Hispanic or Latino
White
Native Hawaiian/Other Pacific Islander
*All races are non-Hispanic. Persons reporting two or more races accounted for less than 1% of all cases.

10. Reported TB Cases by Race/Ethnicity* United States, 2007
American Indian or
Alaska Native (1%)
White
(17%)
Asian
(26%)
Native Hawaiian or
Other Pacific Islander (<1%)
Hispanic or Latino
(29%)
Black or
African-American
(26%)
*All races are non-Hispanic. Persons reporting two or more races accounted for less than 1% of all cases.

11. Number of TB Cases in U. S. -born vs
Number of TB Cases in U.S.-born vs. Foreign-born Persons United States, 1993–2007*
No. of Cases
*Updated as of April 23, 2008.

12. Trends in TB Cases in Foreign-born Persons, United States, 1987–2007*
No. of Cases
Percentage
*Updated as of April 23, 2008.

13. Reported TB Cases by Origin and Race/Ethnicity,* United States, 2007
U.S.-born
Foreign-born**
American Indian or Alaska Native (3%)
White (5%)
Asian (2%)
Hispanic or Latino (38%)
White (33%)
Asian (43%)
Black or African American (45%)
Native Hawaiian/Other
Pacific Islander (<1%)
Hispanic or Latino (17%)
Black or African
American (13%)
*All races are non-Hispanic. Persons reporting two or more races accounted for less than 1% of all cases.
**American Indian or Alaska Native and Native Hawaiian or Other Pacific Islander accounted for less than 1% of foreign-born cases and are not shown.

14. Percentage of TB Cases Among Foreign-born Persons, United States*
1997
2007 DC DC
>50%
25%–49%
<25%
*Updated as of April 23, 2008.

15. TB Case Rates in U. S. -born vs
TB Case Rates in U.S.-born vs. Foreign-born Persons United States, 1993–2007*
Cases per 100,000
*Updated as of April 23, 2008.

16. TB Case Rates in U. S. -born vs. Foreign-born Persons United States,
Cases per 100,000
*Includes the same data as slide 15, but rates presented on a logarithmic scale.
**Updated as of April 23, 2008.

17. Countries of Birth of Foreign-born Persons Reported with TB United States, 2007
Mexico
(24%)
Other
Countries
(39%)
Philippines
(12%)
Rep. Korea
(2%)
Viet Nam
(7%)
Haiti
(2%)
India
(8%)
China
(5%)

18. Percent of Foreign-born with TB by Time of Residence in U. S
Percent of Foreign-born with TB by Time of Residence in U.S. Prior to Diagnosis, 2007
* Foreign-born TB patients for whom information on length of residence in the U.S. prior to diagnosis is unknown or missing.

19. Primary Anti-TB Drug Resistance United States, 1993–2007*
% Resistant
*Updated as of April 23, 2008.
Note: Based on initial isolates from persons with no prior history of TB.
Multidrug resistant TB (MDR TB) is defined as resistance to at least isoniazid and rifampin.

20. Primary MDR TB United States, 1993–2007*
No. of Cases
Percentage
*Updated as of April 23, 2008.
Note: Based on initial isolates from persons with no prior history of TB.
MDR TB defined as resistance to at least isoniazid and rifampin.

21. Primary Isoniazid Resistance in U. S. -born vs
Primary Isoniazid Resistance in U.S.-born vs. Foreign-born Persons United States, 1993–2007*
% Resistant
*Updated as of April 23, 2008.
Note: Based on initial isolates from persons with no prior history of TB.

22. Primary MDR TB in U. S. -born vs
Primary MDR TB in U.S.-born vs. Foreign-born Persons, United States, 1993–2007*
% Resistant
*Updated as of April 23, 2008.
Note: Based on initial isolates from persons with no prior history of TB.
MDR TB defined as resistance to at least isoniazid and rifampin.

23. XDR TB Case Count defined on Initial DST† by Year, 1993–2007*
Year of Diagnosis
†Drug susceptibility test.
*Reported incident cases as of April 23, 2008.
Extensively drug-resistant TB (XDR TB) is defined as resistance to isoniazid and rifampin,
plus resistance to any fluoroquinolone and at least one of three injectable second-line anti-TB drugs.

24. Reporting of HIV Test Results in Persons with TB by Age Group United States, 1993–2006*
% with Test Results
2006
*Updated as of April 23, 2008.
Note: Includes TB patients with positive, negative, or indeterminate HIV test results. Persons from California reported with AIDS only through 2004.
(HIV test results are not reported from California)

25. Estimated HIV Coinfection in Persons Reported with TB, United States, 1993–2006*
*Updated as of April 23, 2008.
Note: Minimum estimates based on reported HIV-positive status
among all TB cases in the age group.

26. Mode of Treatment Administration in Persons Reported with TB United States, 1993–2005*
*Updated as of April 23, 2008.
Directly observed therapy (DOT); Self-administered therapy (SA)

27. Completion of TB Therapy United States, 1993–2005***
Percentage
*Updated as of April 23, 2008.
**Healthy People 2010 target: 90% completed in 1 yr or less.
Note: Persons with initial isolate resistant to rifampin and children under 15 years old with meningeal, bone or joint, or miliary disease excluded.